Biogen Pharmachem Industries Ltd
₹ 0.74
0.00%
05 Dec
1:16 p.m.
About
Incorporated in 1995, Biogen Pharmachem Industries Ltd is in the business of trading
in shares and securities.[1]
Key Points
- Market Cap ₹ 66.8 Cr.
- Current Price ₹ 0.74
- High / Low ₹ 1.29 / 0.73
- Stock P/E 38.8
- Book Value ₹ 1.10
- Dividend Yield 0.00 %
- ROCE -0.39 %
- ROE -0.39 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Stock is trading at 0.67 times its book value
Cons
- Company has a low return on equity of 0.78% over last 3 years.
- Earnings include an other income of Rs.1.44 Cr.
- Working capital days have increased from 67.5 days to 170 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Financial Services Financial Services Finance Other Financial Services
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.95 | 0.00 | 1.62 | 2.47 | 0.00 | 2.38 | 1.20 | 1.58 | |
| 0.03 | 0.04 | 0.03 | 0.12 | 6.72 | 0.95 | 0.12 | 3.22 | 2.49 | 0.45 | 0.45 | 1.49 | 1.30 | |
| Operating Profit | -0.03 | -0.04 | -0.03 | -0.12 | -6.61 | 0.00 | -0.12 | -1.60 | -0.02 | -0.45 | 1.93 | -0.29 | 0.28 |
| OPM % | -6,009.09% | 0.00% | -98.77% | -0.81% | 81.09% | -24.17% | 17.72% | ||||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 | 0.91 | 0.00 | 0.00 | 1.44 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.13 | -0.14 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 1.72 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| -0.13 | -0.13 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 1.72 | |
| EPS in Rs | -0.00 | -0.00 | -0.00 | -0.00 | -0.10 | 0.00 | -0.00 | -0.02 | -0.00 | 0.01 | 0.03 | -0.00 | 0.02 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -21% |
| TTM: | 129% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 578% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 29% |
| 3 Years: | -5% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 0% |
| 3 Years: | 1% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 90.26 |
| Reserves | -4.14 | -4.27 | -4.30 | -4.42 | -10.98 | -10.99 | -9.51 | -11.12 | -11.13 | -10.67 | -8.74 | 26.67 | 8.82 |
| 57.21 | 10.00 | 6.21 | 0.72 | 0.01 | 0.63 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 4.93 | 2.49 | 1.64 | 1.69 | 1.64 | 2.73 | 0.03 | 0.11 | 0.82 | 0.24 | 0.30 | 0.09 | 0.10 | |
| Total Liabilities | 123.26 | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.18 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 60.86 | 43.78 | 26.69 | 22.39 | 3.52 | 6.25 | 6.45 | 9.49 | 6.95 | 8.85 | 5.44 | 23.84 | 21.37 |
| 62.40 | 29.70 | 42.12 | 40.86 | 52.41 | 51.38 | 49.64 | 44.76 | 48.00 | 45.98 | 51.38 | 68.18 | 77.81 | |
| Total Assets | 123.26 | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.18 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.05 | -7.28 | 4.68 | -0.07 | -13.65 | 0.09 | -1.21 | 3.95 | 1.40 | 1.70 | 1.94 | -1.08 | |
| -8.99 | 17.08 | 17.08 | 4.30 | 14.32 | -0.72 | 1.54 | -3.64 | -1.32 | -1.66 | -2.06 | -32.62 | |
| 10.33 | -11.19 | -21.74 | -4.31 | -0.71 | 0.62 | -0.32 | -0.31 | 0.00 | 0.00 | 0.00 | 35.70 | |
| Net Cash Flow | 1.39 | -1.38 | 0.02 | -0.07 | -0.03 | -0.02 | 0.00 | 0.00 | 0.08 | 0.05 | -0.11 | 2.00 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | ||||||
| Inventory Days | 0.00 | 0.00 | 0.00 | |||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | ||||||
| Working Capital Days | 23,194.09 | 2,651.05 | 549.75 | 152.21 | -35.27 | 170.33 | ||||||
| ROCE % | -0.14% | -0.15% | -0.04% | -0.19% | -11.32% | 0.00% | -0.22% | -2.90% | -0.02% | -0.37% | 3.47% | -0.39% |
Documents
Announcements
-
Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
7 Nov - No unutilized proceeds from any issue as of 30 Sep 2025; disclosure dated 07.11.2025.
-
Regulations 30, 33 And Other Applicable Provisions Of The SEBI (LODR) Regulations, 2015
7 Nov - Biogen Pharmachem declares no unutilized proceeds from past issues as of 30 Sep 2025.
-
Regulations 30, 33 And Other Applicable Provisions Of The SEBI (LODR) Regulations, 2015
7 Nov - Board approved unaudited results for quarter and H1 ended 30 Sep 2025; Q2 loss Rs49.15 lakh.
-
Board Meeting Outcome for Outcome Of The Board Meeting Of The Board Held On 7Th November 2025.
7 Nov - Approved unaudited Q2/H1 results for period ended 30 Sep 2025; paid-up capital Rs9,026.03 lakh.
-
Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting
30 Oct - Board meeting on 7 Nov 2025 to approve unaudited Q2 and H1 results ended 30 Sep 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
BPIL is engaged in the business of trading in shares and securities in the present and future markets. It trades in commodities, including agro-based and precious metals, and other goods. The company also provides stock broking and consulting services. In addition, it generates trades and sells wind power